Rodríguez-Izquierdo, ISerramía, M JGómez, REspinosa, GGenebat, MLeal, MMuñoz-Fernandez, M A2023-05-032023-05-032022-03-21http://hdl.handle.net/10668/20323The absence of an effective treatment and vaccine in HIV-1 pandemic place preventive strategies such as safety and effective microbicide development as a central therapeutic approach to control HIV-1 pandemic nowadays. Studies of cytotoxicity, immune population status, inflammation or tissue damage and mainly prophylactic inhibition of HIV-1 infection in vaginal human explants demonstrate the biosafety and effectivity of G2-S16 dendrimer. Human explants treated with G2-S16 dendrimer or treated and HIV-1 infected do not presented signs of irritation, inflammation, immune activation or T cell populations deregulation. Herein we conclude that G2-S16 dendrimer has demonstrated sufficient efficacy, biosafety, effectivity and behavior in the closest to the real-life condition model represented by the human healthy donor vaginal tissue explants, to raise G2-S16 dendrimer as a promising candidate to clinical trials to develop an effective microbicide against HIV-1 infection.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/EfficacyG2-S16HIV-1MicrobicideSafetyVaginal explantsAnti-Infective AgentsDendrimersFemaleHIV-1HumansVaginaresearch article35307031open access10.1186/s12951-022-01350-81477-3155PMC8935742https://jnanobiotechnology.biomedcentral.com/track/pdf/10.1186/s12951-022-01350-8https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935742/pdf